Market closedNon-fractional
Terns Pharmaceuticals/TERN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Terns Pharmaceuticals
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
Ticker
TERN
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Foster City, United States
Employees
66
Website
www.ternspharma.com
TERN Metrics
BasicAdvanced
$569M
Market cap
-
P/E ratio
-$1.26
EPS
-0.50
Beta
-
Dividend rate
Price and volume
Market cap
$569M
Beta
-0.5
Financial strength
Current ratio
27.854
Quick ratio
27.26
Total debt to equity
0.18
Management effectiveness
Return on assets (TTM)
-23.69%
Return on equity (TTM)
-34.73%
Valuation
Price to book
2.39
Price to tangible book (TTM)
2.39
Price to free cash flow (TTM)
-8.388
Growth
Earnings per share change (TTM)
-12.92%
3-year earnings per share growth (CAGR)
-46.86%
What the Analysts think about TERN
Analyst Ratings
Majority rating from 8 analysts.
TERN Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$22M
6.19%
Profit margin
0.00%
NaN%
TERN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.25
-$0.42
-$0.29
-$0.30
-
Expected
-$0.34
-$0.31
-$0.29
-$0.34
-$0.34
Surprise
-26.23%
37.45%
-0.76%
-11.11%
-
TERN News
AllArticlesVideos
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation
GlobeNewsWire·1 month ago
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewsWire·2 months ago
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Terns Pharmaceuticals stock?
Terns Pharmaceuticals (TERN) has a market cap of $569M as of July 27, 2024.
What is the P/E ratio for Terns Pharmaceuticals stock?
The price to earnings (P/E) ratio for Terns Pharmaceuticals (TERN) stock is 0 as of July 27, 2024.
Does Terns Pharmaceuticals stock pay dividends?
No, Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Terns Pharmaceuticals dividend payment date?
Terns Pharmaceuticals (TERN) stock does not pay dividends to its shareholders.
What is the beta indicator for Terns Pharmaceuticals?
Terns Pharmaceuticals (TERN) has a beta rating of -0.5. This means that it has an inverse relation to market volatility.
Buy or sell Terns Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.